벡톤 디킨슨 앤 코 (BDX) 회사 소개
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems.
It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Becton, Dickinson and Company는 전 세계의 의료기관, 의사, 생명과학 연구자, 임상검사실, 제약업계 및 일반 소비자를 대상으로 의료용 소모품, 기기, 실험실 장비 및 진단제품을 개발·제조·판매합니다. 사업은 Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences의 4개 세그먼트로 운영됩니다.
제품 포트폴리오는 peripheral intravenous (IV) 및 advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extension sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems 등을 포함합니다. 또한 IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, medication inventory optimization and tracking system, hemodynamic monitoring system, prefillable drug delivery systems 등 약물관리 및 주입 관련 솔루션을 제공합니다. 검사 관련으로는 specimen and blood collection products, automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, rapid diagnostic assays, microbiology laboratory automation products, plated media products 및 fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, solution for single-cell gene expression analysis, 임상종양·면역·이식 진단·모니터링 시약과 분석기 등이 포함됩니다.
또한 hernia and soft tissue repair, biological and bioresorbable graft, biosurgery 및 기타 외과용 제품과 surgical infection prevention, peripheral intervention, urology and critical care 제품도 제공합니다. 회사는 의료현장의 유해약물 오염 검사 개선을 위해 ChemoGLO와 전략적 협업을 진행하고 있으며, 1897년에 설립되어 본사는 뉴저지주 Franklin Lakes에 있습니다.
주소: 1 Becton Drive, Franklin Lakes, NJ 07417-1880, United States
전화번호: 201 847 6800
웹사이트: https://www.bd.com
섹터: Healthcare
산업: Medical Instruments & Supplies
직원 수: 72,000
BDX STOCK CHART
BDX 주가 차트 (1년)
벡톤 디킨슨 앤 코 BDX LATEST NEWS
최신뉴스: 2일 전BDX LATEST NEWS
벡톤 디킨슨 앤 코 최신 뉴스
벡톤 디킨슨 앤 코 관련 주요 소식과 시장 반응
최근 배당 정보Finviz Dividend Snapshot
| 항목 | 값 |
|---|---|
| Dividend Est. | 3.99 (2.23%) |
| Dividend TTM | 3.98 (2.22%) |
| Dividend Ex-Date | Sep 09, 2026 |
| Dividend Gr. 3/5Y | 6.13% 5.65% |
| Payout | 71.53% |
| P/E | 54.06 |
배당 지급 이력Dividend payout history
| 배당락일Ex-date | 배당금Amount | 특별배당Special |
|---|---|---|
| Sep 9, 2026 | 1.05 | 0.00 |
| Jun 9, 2026 | 1.05 | 0.00 |
| Mar 10, 2026 | 1.05 | 0.00 |
| Feb 10, 2026 | 0.00 | 44.41 |
| Dec 8, 2025 | 0.83 | 0.23 |
| Sep 8, 2025 | 0.82 | 0.22 |
| Jun 9, 2025 | 0.82 | 0.22 |
| Mar 10, 2025 | 0.82 | 0.22 |
| Dec 9, 2024 | 0.82 | 0.22 |
| Sep 9, 2024 | 0.75 | 0.20 |
BDX TARGET PRICE 2026
BDX TARGET PRICE
BDX 목표주가
| 날짜 | 의견 | 애널리스트 | 투자의견 | 목표가 변경 |
|---|---|---|---|---|
| Jul-28-26 | 신규Initiated | UBS | 매수 Buy | $19 |
| May-04-26 | 분석 재개Resumed | Evercore ISI | 시장수익률상회 Outperform | $180 |
| Apr-10-26 | 분석 재개Resumed | Goldman | 중립 Neutral | $167 |
| Feb-10-26 | 분석 재개Resumed | Barclays | 비중확대 Overweight | $202 |
| Feb-03-26 | 분석 재개Resumed | Citigroup | 매수 Buy | $233 |
| Sep-25-25 | 신규Initiated | RBC Capital Mkts | Sector Perform | $211 |
| May-22-25 | 하향Downgrade | Citigroup | Buy → Neutral | $185 |
| May-02-25 | 하향Downgrade | Raymond James | Outperform → Mkt Perform | |
| May-02-25 | 하향Downgrade | Piper Sandler | Overweight → Neutral | $185 |
| May-02-25 | 하향Downgrade | Goldman | Buy → Neutral | $192 |
| May-01-25 | 하향Downgrade | William Blair | Outperform → Mkt Perform | |
| May-01-25 | 하향Downgrade | Wells Fargo | Overweight → Equal Weight | |
| May-01-25 | 하향Downgrade | BofA Securities | Buy → Neutral | $190 |
| Oct-01-24 | 상향Upgrade | Citigroup | Neutral → Buy | $255 → $275 |
| May-30-24 | 신규Initiated | Goldman | 매수 Buy | $274 |
| Jul-24-23 | 상향Upgrade | Raymond James | Mkt Perform → Outperform | $305 |
| May-30-23 | 분석 재개Resumed | Morgan Stanley | 비중확대 Overweight | $295 |
| May-05-23 | 상향Upgrade | Piper Sandler | Neutral → Overweight | $260 → $290 |
| Apr-12-23 | 상향Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight | $304 |
| Jan-03-23 | 상향Upgrade | BofA Securities | Neutral → Buy | $250 → $290 |
✍️ 최근 5일 BDX 차트분석
벡톤 디킨슨 앤 코 (BDX) 차트분석
벡톤 디킨슨 앤 코의 최근 5일 흐름, 단기 매물대, 이동평균 저항/지지와 시뮬레이션 차트는 별도 차트분석 페이지에서 확인할 수 있습니다.
차트분석 페이지 보기벡톤 디킨슨 앤 코 (BDX) 최근 실적발표
벡톤 디킨슨 앤 코의 EPS, 매출, 실적 발표일과 관련 차트는 내부 실적발표 페이지에서 확인할 수 있습니다.
실적발표 페이지 보기


